Cargando…

Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab

BACKGROUND: Clinically validated biomarkers for monitoring of patients with complement-mediated thrombotic microangiopathy (CM-TMA) including atypical hemolytic uremic syndrome (aHUS) are unavailable. Improved characterization of biomarkers in patients with aHUS may inform treatment and monitoring f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cammett, Tobin J., Garlo, Katherine, Millman, Ellen E., Rice, Kara, Toste, Catherine M., Faas, Susan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813049/ https://www.ncbi.nlm.nih.gov/pubmed/36329366 http://dx.doi.org/10.1007/s40291-022-00620-3

Ejemplares similares

Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J, et al.
Publicado: (2023)

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis
por: Fakhouri, Fadi, et al.
Publicado: (2021)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life
por: Legendre, Christophe, et al.
Publicado: (2021)

Atypical hemolytic uremic syndrome (aHUS) responsive to mycophenolate mofetil: A case report from Nepal
por: Gurung, Jyoti, et al.
Publicado: (2022)

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Ohanian, Maro, et al.
Publicado: (2011)

Baseline characteristics and evolution of Brazilian patients with atypical hemolytic uremic syndrome: first report of the Brazilian aHUS Registry
por: Vaisbich, Maria Helena, et al.
Publicado: (2022)

Thrombotic microangiopathy (aHUS/iTTP) reported so far in Covid-19 patients: The virus alone or an omnium gatherum of mechanisms and etiologies?
por: Mir, Tajamul H.
Publicado: (2021)

Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry
por: Halimi, Jean-Michel, et al.
Publicado: (2022)

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
por: Mauch, Teri J, et al.
Publicado: (2023)

Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)

Eculizumab and aHUS: Spotlight on Patient-Centered Care
por: Rafat, Cédric, et al.
Publicado: (2020)

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
por: Kelen, Kata, et al.
Publicado: (2023)

Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
por: Pape, Lars, et al.
Publicado: (2016)

Atypical Hemolytic Uremic Syndrome (aHUS) and Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)—Two Diseases That Exacerbate Each Other: Case Report
por: Bogdał, Anna, et al.
Publicado: (2021)

Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome
por: Shen, Yu-Min
Publicado: (2016)

aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2010)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

The global aHUS registry: methodology and initial patient characteristics
por: Licht, Christoph, et al.
Publicado: (2015)

Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States
por: Wang, Yan, et al.
Publicado: (2023)

Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA
por: Ponraj, Royston, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
por: Barbour, Thomas, et al.
Publicado: (2021)

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients
por: Levandovsky, Mark, et al.
Publicado: (2008)

Relevance of Bacteriophage 933W in the Development of Hemolytic Uremic Syndrome (HUS)
por: Del Cogliano, Manuel E., et al.
Publicado: (2018)

Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)
por: Scheiring, Johanna, et al.
Publicado: (2008)

Thrombotic Microangiopathy with Complement Factor H Gene Mutations Unassociated with Atypical Hemolytic Uremic Syndrome
por: Oymak, Yeşim, et al.
Publicado: (2015)

Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort
por: Nga, Hong Si, et al.
Publicado: (2021)

Erratum to: aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2012)

Can eculizumab be discontinued in aHUS?: Case report and review of the literature
por: Sahutoglu, Tuncay, et al.
Publicado: (2016)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
por: Lokki, A. Inkeri, et al.
Publicado: (2020)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?
por: Spasiano, Andrea, et al.
Publicado: (2023)

Compound Haplotype Variants in CFH and CD46 Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)—A Series of Cases from a Single Family
por: Furmańczyk-Zawiska, Agnieszka, et al.
Publicado: (2021)

Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review
por: Wu, Xiaoyan, et al.
Publicado: (2021)

Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab
por: Ehren, Rasmus, et al.
Publicado: (2021)

Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
por: Schmidt, Tilman, et al.
Publicado: (2022)

Eculizumab Versus Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome: A Systematic Review
por: Shahid, Kamran, et al.
Publicado: (2023)

Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS)
por: Goldwater, Paul N, et al.
Publicado: (2012)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
por: Yenerel, Mustafa N.
Publicado: (2014)

A comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT score
por: Addad, Vanessa Vilani, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mi80cq7sfgvjcpdbf6c06h395d